The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
Claims What is claimed is: 1. A method of preventing or treating a condition in a patient, said condition being selected from cerebral apoplexy, craniocerebral trauma, and a combination of cerebral apoplexy and craniocerebral trauma, said method comprising administering to said patient an amount of an agonist of the cannabinoid receptor CB1 which is effective to prevent or treat said condition. 2. The method according to claim 1, wherein the condition is cerebral apoplexy. 3. The method according to claim 1, wherein the condition is craniocerebral trauma. 4. The method according to claim 1, wherein the condition is a combination of cerebral apoplexy and craniocerebral trauma. 